Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LFnp24B.C therapeutic HIV vaccine plus ART in virologically suppressed adults with HIV-1 infection
CTR20202666Phase 2Active
- Sponsor
- Haikou VTI Biological Institute
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of LFn-p24B.C in Human immunodeficiency virus infection type 1, sponsored by Haikou VTI Biological Institute. Started Jan 2021; status: active.
02
Drugs
LFn-p24B.C
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20202666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202666.